Spyre Therapeutics Inc. (SYRE) has announced the pricing for its underwritten public offering, which includes approximately 7.28 million shares of its common stock, each priced at $27.50. The company anticipates gross proceeds totaling $200 million from this offering, prior to subtracting underwriting discounts, commissions, and related expenses.
Additionally, the company has provided the underwriters with a 30-day option to purchase up to an extra 1.09 million shares of common stock at the public offering price, excluding the underwriting discount. The offering is expected to conclude by November 20, 2024.
